Wen-Kai Ge1, Ben Yang2, Wen-Shu Zuo2, Gang Zheng2, Ying-Qi Dai3, Chao Han3, Li Yang2, Mei-Zhu Zheng2. 1. School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Shandong Cancer Hospital Jinan, China; Department of Surgery II, Shandong Breast Center of Prevention and Treatment, Shandong Cancer Hospital Jinan, China. 2. Department of Surgery II, Shandong Breast Center of Prevention and Treatment, Shandong Cancer Hospital Jinan, China. 3. School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Shandong Cancer Hospital Jinan, China.
Abstract
BACKGROUND: The aim of this study was to investigate the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuant chemotherapy (NAC) in breast cancer patients with confirmed axillary nodal metastases. METHODS: We enrolled 51 patients with breast cancer who received NAC. All patients were proven to have axillary nodal metastases by histopathology biopsy prior to NAC. They all underwent SLNB before breast surgery, and complete axillary lymph node dissection immediately followed. RESULTS: The identification rate for SLNB was 87.5% (84/96); the false negative rate was 24.5% (12/49). The clinicopathological factors were not significantly correlated with the identification and false negative rate of the SLNB. Lymphatic mapping, blue dye or radionuclide methods tended to decrease the identification rate of SLNB (P = 0.073). Clinical nodal status before NAC has a trend to increase the false-negative rates of the SLNB (P = 0.059). For patients with N1 clinical axillary lymph nodal status, the identification rate was 93.9%, and the false negative rate was 5.9%, compared with N2-3 patients with 73.9% and 38.9%, respectively. CONCLUSIONS: SLNB is feasible for the patients whose axillary lymph nodal status before NAC is N1. However, for N2-3 patients, SLNB cannot be used as an infallible indicator of non-SLN status.
BACKGROUND: The aim of this study was to investigate the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuant chemotherapy (NAC) in breast cancerpatients with confirmed axillary nodal metastases. METHODS: We enrolled 51 patients with breast cancer who received NAC. All patients were proven to have axillary nodal metastases by histopathology biopsy prior to NAC. They all underwent SLNB before breast surgery, and complete axillary lymph node dissection immediately followed. RESULTS: The identification rate for SLNB was 87.5% (84/96); the false negative rate was 24.5% (12/49). The clinicopathological factors were not significantly correlated with the identification and false negative rate of the SLNB. Lymphatic mapping, blue dye or radionuclide methods tended to decrease the identification rate of SLNB (P = 0.073). Clinical nodal status before NAC has a trend to increase the false-negative rates of the SLNB (P = 0.059). For patients with N1 clinical axillary lymph nodal status, the identification rate was 93.9%, and the false negative rate was 5.9%, compared with N2-3 patients with 73.9% and 38.9%, respectively. CONCLUSIONS: SLNB is feasible for the patients whose axillary lymph nodal status before NAC is N1. However, for N2-3 patients, SLNB cannot be used as an infallible indicator of non-SLN status.
Authors: José Roberto M Piato; Alfredo Carlos S D Barros; Kátia M Pincerato; Ana Paula Q Sampaio; José Aristodemo Pinotti Journal: Eur J Surg Oncol Date: 2003-03 Impact factor: 4.424
Authors: K S Nason; B O Anderson; D R Byrd; L K Dunnwald; J F Eary; D A Mankoff; R Livingston; R A Schmidt; K D Jewell; R S Yeung; R E Moe Journal: Cancer Date: 2000-12-01 Impact factor: 6.860
Authors: A Fernández; M Cortés; E Benito; D Azpeitia; L Prieto; A Moreno; Y Ricart; J Mora; A Escobedo; J Martín Comín Journal: Nucl Med Commun Date: 2001-04 Impact factor: 1.690
Authors: Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys Journal: Breast Date: 2003-10 Impact factor: 4.380
Authors: Erika A Newman; Michael S Sabel; Alexis V Nees; Anne Schott; Kathleen M Diehl; Vincent M Cimmino; Alfred E Chang; Celina Kleer; Daniel F Hayes; Lisa A Newman Journal: Ann Surg Oncol Date: 2007-05-19 Impact factor: 5.344
Authors: P Gimbergues; C Abrial; X Durando; G Le Bouedec; F Cachin; F Penault-Llorca; M A Mouret-Reynier; F Kwiatkowski; J Maublant; A Tchirkov; J Dauplat Journal: Ann Surg Oncol Date: 2008-03-01 Impact factor: 5.344
Authors: Janine M Simons; Thiemo J A van Nijnatten; Carmen C van der Pol; Ernest J T Luiten; Linetta B Koppert; Marjolein L Smidt Journal: Ann Surg Date: 2019-03 Impact factor: 12.969